CSL licenses Eli Lilly’s clazakizumab to cut cardiac risk in end-stage kidney disease

CSL licenses Eli Lilly’s clazakizumab to cut cardiac risk in end-stage kidney disease

Feb 18 (Reuters) – Australia’s CSL said on Wednesday it had entered into an exclusive ​licensing agreement with Eli ‌Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related ‌illness ​and death in ⁠people with end‑stage ⁠kidney disease. CSL will receive an upfront payment of $100 million and be eligible to receive potential ​clinical, regulatory and commercial milestone pay…

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

CSL will need more than $100 million to recover from its current difficulties, but it’s a start. Eli Lilly has paid the nine-figure sum upfront for rights to the Australian company’s anti ...

CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background

CSL Ltd shares rose as much as 2.1% Wednesday after announcing a $100 million licensing deal with Eli Lilly for the kidney drug clazakizumab. CSL closed up 0.78% at A$152.74. The company also bought back 50,829 shares Tuesday, bringing total repurchases to over 3.2 million. The ASX200 index edged up 0.16%. The post CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background appeared first on TechStock².

Lunch Wrap: Big banks and CSL light up as ASX edges higher

ASX edges higher as banks do the heavy lifting NAB jumps 5% to record highs after $2bn quarter CSL gains on US$100m Eli Lilly licensing deal   Australia’s earnings season kept the ASX in positive territory at lunchtime in the eastern states, with big banks and CSL doing the heavy lifting. Around 1pm (AEDT) the ASX 200 was up 25.60 points or 0.29% to 8984.50 points. Overnight in the US, markets were largely flat after returning from the President…